English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Prostate cancer is a common cancer among men in developed countries. Althoughhormonotherapy and radiotherapy (RT) represent valid therapies for prostate cancertreatment, novel immunological approaches have been explored. The developmentof clinical trials employing cancer vaccines has indicated that immune responseto tumor antigens can be boosted and that vaccine administration can improve patientsurvival. Immune response to tumor antigens could also be enhanced after standardtherapies. In the present study, we determined the occurrence of antibodies toextracellular matrix (ECM) molecules, heat shock protein (HSP), ribosomal P0 protein,EGFR, ErbB2 and prostate-specific antigen (PSA) in 35 prostate cancer patientsprior to and following local RT and hormonotherapy. We demonstrated that immunityto P0, ECM molecules [collagens (C) CI, CIII, CV, fibronectin (FN) and laminin(LM)] and to HSP90 was associated with malignancy in untreated patients. Noneof the patient sera showed antibodies to EGFR, while 2 and 1 patients showed reactivityto ErbB2 and PSA, respectively. We also demonstrated that 8 months after therapythe IgG serum levels to CI, CIII, FN and HSP90 significantly decreased. Conversely,the level of P0 autoantibodies increased after therapy in 10 patients. Five ofthe 10 patients with increased levels of P0 autoantibodies were treated with RTplus hormonotherapy. Treatment of patients did not change the levels of antibodiesagainst EGFR, ErbB2 and PSA. Our results indicated that the modification of antibodylevel to self molecules after standard treatment of prostate cancer patients isinfluenced by the type of antigen. Ribosomal P0 protein appears to be a high immunogenicantigen and its immunogenicity increases following RT. In addition, 10 patientswith increased levels of autoantibodies to P0 showed PSA mean levels lower thanthe remaining 25 patients at 18 months. This study may contribute to a betterunderstanding of the immunobiological behavior of prostate cancer patients followingstandard treatment.

oncology reports

Local radiotherapy increases the level of autoantibodies to ribosomal P0 protein but not to heat shock proteins, extracellular matrix molecules and EGFR/ErbB2 receptors in prostate cancer patients